ProKidney (PROK) announced the appointment of Greg Madison as chief commercial officer. In this role, Madison will drive ProKidney’s commercial strategy as the company advances towards the potential commercialization of rilparencel. Most recently, he served as CEO of Shield Therapeutics (SHIEF).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROK:
- Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
- ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating
- ProKidney reports Q4 EPS (52c), consensus (15c)
- Optimized PROACT 1 Design, Preserved Statistical Power, and Clear Regulatory Path Support Buy Rating on ProKidney
- ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating